SEGMENT REPORTING

6 Months Ended

Jun. 30, 2016

Segment Reporting [Abstract]

SEGMENT REPORTING

SEGMENT REPORTING

The Company consists of two reportable segments, Core Companion Animal Health ("CCA") and Other Vaccines, Pharmaceuticals and Products ("OVP"). The Core Companion Animal Health segment includes diagnostic instruments and supplies, as well as single use diagnostic and other tests, pharmaceuticals and vaccines, primarily for canine and feline use. The CCA segment also includes digital radiography and ultrasound products along with embedded software and support, data hosting and other services from Heska Imaging. These products are sold directly by the Company as well as through independent third-party distributors and through other distribution relationships. CCA segment products manufactured at the Des Moines, Iowa production facility included in the OVP segment's assets are transferred at cost and are not recorded as revenue for the OVP segment. The Other Vaccines, Pharmaceuticals and Products segment includes private label vaccine and pharmaceutical production, primarily for cattle, but also for other animals including small mammals. All OVP products are sold by third parties under third-party labels.

Summarized financial information concerning the Company's reportable segments is shown in the following table (in thousands):

Three Months Ended June 30, 2015	Core Companion Animal Health		Other Vaccines, Pharmaceuticals and Products		Total
Total revenue	$	20,757	$	3,153	$	23,910
Operating Income	1,536		293		1,829
Income before income taxes	1,511		281		1,792
Capital expenditures	142		189		331
Depreciation and amortization	894		174		1,068

Three Months Ended June 30, 2016	Core Companion Animal Health		Other Vaccines, Pharmaceuticals and Products		Total
Total revenue	$	24,464	$	5,501	$	29,965
Operating Income	2,746		810		3,556
Income before income taxes	2,724		798		3,522
Capital expenditures	82		381		463
Depreciation and amortization	915		200		1,115

Six Months Ended June 30, 2015	Core Companion Animal Health		Other Vaccines, Pharmaceuticals and Products		Total
Total revenue	$	40,329	$	6,475	$	46,804
Operating Income	2,071		779		2,850
Income before income taxes	1,921		755		2,676
Capital expenditures	449		487		936
Depreciation and amortization	1,724		350		2,074

Six Months Ended June 30, 2016	Core Companion Animal Health		Other Vaccines, Pharmaceuticals and Products		Total
Total revenue	$	47,898	$	9,213	$	57,111
Operating Income	4,504		1,022		5,526
Income before income taxes	4,532		1,093		5,625
Capital expenditures	479		889		1,368
Depreciation and amortization	1,812		399		2,211

Revenue is attributed to individual countries based on customer location. Total revenue by principal geographic area was as follows (in thousands):

	Three Months Ended June 30,				Six Months Ended June 30,
	2015		2016		2015		2016
United States	$	22,926	$	28,908	$	44,339	$	54,729
Europe	515		567		1,046		1,120
Other International	469		490		1,419		1,262
Total	$	23,910	$	29,965	$	46,804	$	57,111

Asset information by reportable segment as of December 31, 2015 is as follows (in thousands):

	Core Companion Animal Health		Other Vaccines, Pharmaceuticals and Products		Total
Total assets	$	92,567	$	17,152	$	109,719
Net assets	48,175		15,353		63,528

Asset information by reportable segment as of June 30, 2016 is as follows (in thousands):

	Core Companion Animal Health		Other Vaccines, Pharmaceuticals and Products		Total
Total assets	$	95,829	$	23,796	$	119,625
Net assets	59,303		16,355		75,658

Total assets by principal geographic areas were as follows (in thousands):

	December 31,		June 30,
	2015		2016
United States	$	106,780	$	116,552
Europe	2,939		3,073
Total	$	109,719	$	119,625